serum pepsinogen (PG) tests correlate with the occurrence of gastric atrophy and intestinal metaplasia. However, because of its low sensitivity, Huang et al report that in North America, where Helicobacter pylori prevalence is low (8%) and the use of proton pump inhibitors is frequent, the discrimination value for gastric preneoplastic lesions, atrophic gastritis, and intestinal metaplasia of gastropanel biomarkers is too low to obtain good results.
